Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Cell And Gene Therapy Clinical Milestones Highlight Reimbursement Challenges

This article was originally published in Scrip

Executive Summary

The Stem Cell Meeting on the Mesa began on Oct. 7 in San Diego just a few days after Spark Therapeutics posted positive Phase III results that could support the first-ever US FDA approval of a gene therapy, but the achievement and the conference highlighted a still-unsolved challenge for regenerative medicines: How will health care systems pay for curative, one-time treatments?



Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst